GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (FRA:0FY) » Definitions » Profitability Rank

Equillium (FRA:0FY) Profitability Rank : 0 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Equillium Profitability Rank?

Equillium has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Equillium's Operating Margin % for the quarter that ended in Dec. 2023 was -34.74%. As of today, Equillium's Piotroski F-Score is 3.


Competitive Comparison of Equillium's Profitability Rank

For the Biotechnology subindustry, Equillium's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Equillium's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Equillium's Profitability Rank falls into.



Equillium Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Equillium has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Equillium's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-2.934 / 8.446
=-34.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Equillium has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Equillium Profitability Rank Related Terms

Thank you for viewing the detailed overview of Equillium's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Equillium (FRA:0FY) Business Description

Traded in Other Exchanges
Address
2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Equillium (FRA:0FY) Headlines

No Headlines